GET DAILY SIGNALSAlamar Biosciences (ALMR): Path to a +35% Advance Toward the $37 Target
Key Takeaways
- The central target of $37 is the arithmetic mean of five verified analyst price targets, which average roughly $36.60.
- Those five targets range widely, from $32 (Stifel) to $45 (Leerink Partners), reflecting genuine disagreement about valuation.
- With the stock near $27, reaching $37 implies a roughly 35% advance — a substantial move for a recently listed, money-losing company.
- Supporting factors include rapid revenue growth, a razor-and-blade consumables model, a strong cash position, and a 4-buy/1-hold analyst split.
- Key risks include persistent net losses, a premium revenue multiple, heavy competition from larger diagnostics players, and post-IPO share volatility.
- Readers can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Investors can also explore Trending AI Robots for AI-driven tools that monitor market conditions and trading signals.
What the Analysts Are Saying
Five analysts currently cover ALMR, and their individual targets produce an average of roughly $36.60, which rounds to the $37 figure used here. The range is unusually wide — from Stifel's $32 (analyst Daniel Arias, Buy) and J.P. Morgan's $35 (Overweight) and Bank of America's $35 (Hold, raised from $31) to TD Cowen's $36 (analyst Dan Brennan, Buy) and Leerink Partners' $45 (Outperform, raised from $35). Four analysts rate the stock a Buy or equivalent, and one (BofA) is at Hold, with no Sell ratings.
The spread between $32 and $45 signals that analysts see the same fundamentals but weigh them very differently. Bulls emphasize consumable pull-through and the NULISA platform's adoption across immunology, neurology, and oncology. More cautious voices, including BofA's Hold, point to the premium valuation and ongoing losses. The mean should be read as a reference point, not a guarantee or a near-term forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where the Stock Stands Today
Shares traded near $27 in early November 2026 after a sharp post-earnings decline, well below the roughly $30.49 50-day moving average and the 52-week high of $39.61. Reaching $37 would require an advance of approximately 35% from that level — a substantial move. The company generated about $100 million in trailing-twelve-month revenue with a gross margin near 59%, guided to roughly $116–120 million for fiscal 2026, and held about $250 million in cash against roughly $51 million in debt. Because the company is unprofitable, the market values it on a revenue multiple rather than a P/E (price-to-earnings) ratio, meaning the path to $37 depends heavily on sustaining high growth and margin expansion.
Factors That Could Drive It Higher
Alamar's razor-and-blade model is a genuine strength: instruments generate recurring consumables and service revenue, and second-quarter 2026 consumables reportedly grew around 147% year over year. The NULISA platform's adoption in Alzheimer's research — including a partnership with the Alzheimer's Disease Data Initiative and Gates Ventures — offers a large addressable market. A net cash position near $199 million provides runway, and recent target increases from TD Cowen, Leerink, and BofA suggest analysts see improving fundamentals. Continued guidance beats and new diagnostic applications could support the premium multiple.
Risks to Watch
The biggest obstacle is valuation. At roughly 18 times trailing revenue, the shares price in sustained, above-market growth, leaving little room for error. Competition is substantial: Olink (now part of Thermo Fisher), SomaScan (Standard BioTools), Quanterix, Bio-Techne, and mass-spectrometry vendors all sell into the same laboratories. Most products are sold for research rather than clinical diagnosis, so any move into regulated diagnostics would add cost and time. Post-IPO dynamics — including a six-month lockup expiration in mid-October 2026 and a thinly traded float — can amplify downside, as the stock's recent volatility shows.
Technical Picture
The shares sit below their 50-day moving average near $30.49 after the post-earnings slide, while the 52-week range of roughly $17 to $39.61 brackets a wide and volatile band. The $39.61 prior high stands as a key resistance level above the $37 target, while the low-to-mid $20s and the $17 low represent major support zones. A sustained move back above the 50-day average would be an early structural signal that sentiment is stabilizing.
What to Keep an Eye On
Analyst price targets typically reflect a roughly 12-month research horizon, though firms rarely state exact timeframes, and the wide $32–$45 range shows assumptions differ materially. Investors should monitor quarterly revenue and consumables pull-through, full-year guidance, gross-margin trends, any progress toward diagnostic applications, and analyst target revisions. Given the company's dependence on growth expectations, broader moves in interest rates and risk appetite for unprofitable small-caps also matter.
AI Daily Buy/Sell Signals
In my own work tracking names like this, I often reference AI Daily Buy/Sell Signals to stay on top of momentum shifts. The tool uses artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile, recently listed name like ALMR, it offers a systematic way to spot potential turning points alongside traditional research.
Final Assessment
The $37 target is the rounded average of five analyst price targets, implying a roughly 35% advance from the current price near $27 — a substantial move for a fast-growing but unprofitable proteomics company. The bull case rests on rapid revenue growth, strong consumables economics, a robust cash balance, and a mostly bullish analyst base. The bear case centers on a demanding revenue multiple, intense competition, and the volatility typical of a small, newly public stock. With targets spanning $32 to $45, the debate is genuinely contested. Whether shares reach $37 will depend on execution, margin expansion, and whether the growth story can justify its valuation — none of which can be guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALMR in downward trend: price dove below 50-day moving average on October 30, 2026
ALMR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 1 of 1 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ALMR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 3 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 4 of 5 cases where ALMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ALMR as a result. In 8 of 8 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ALMR just turned positive on October 21, 2026. Looking at past instances where ALMR's MACD turned positive, the stock continued to rise in 2 of 2 cases over the following month. The odds of a continued upward trend are 90%.
Following a +12.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMR advanced for three days, in 30 of 32 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ALMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.075) is normal, around the industry mean (4.170). P/E Ratio (-38.270) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (20.367) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. ALMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement